Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Inoperable œsophageal Cancer × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 273 Carcinoma, Non-Small-Cell Lung 240 Carcinoma, Renal Cell 142 Neoplasms 98 Neoplasm Metastasis 98 Squamous Cell Carcinoma of Head and Neck 87 Carcinoma, Hepatocellular 86 Colorectal Neoplasms 79 Lung Neoplasms 75 Stomach Neoplasms 58 Pancreatic Neoplasms 55 Carcinoma, Transitional Cell 49 Hodgkin Disease 45 Urinary Bladder Neoplasms 42 Head and Neck Neoplasms 42 Breast Neoplasms 40 Ovarian Neoplasms 37 Triple Negative Breast Neoplasms 33 Small Cell Lung Carcinoma 33 Brain Neoplasms 33 Sarcoma 32 Glioblastoma 32 Prostatic Neoplasms 31 Recurrence 29 Kidney Neoplasms 29 Multiple Myeloma 25 Esophageal Neoplasms 24 Uveal Melanoma 23 Skin Neoplasms 23 Lymphoma 22

Interventions

Nivolumab 1 Ipilimumab 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03437200 2023-02-21

CRUCIAL

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated

Inoperable œsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡